MESOTHELIOMA

This early-stage study is testing a new experimental drug called SGN-MesoC2 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and understand how the drug behaves in the body. The study includes 19 pa…

This is an early-stage study to find a safe dose of a new drug called KFA115, both by itself and combined with an existing immunotherapy (pembrolizumab). It involves about 126 adults with various advanced cancers that have stopped responding to standard treatments. The main goal …

This trial is testing a new treatment for advanced cancers that have spread to the lining of the lungs (pleura), including mesothelioma, lung cancer, and breast cancer. Doctors collect a patient's own immune cells (T cells), genetically modify them to recognize a cancer marker ca…

This study tested pembrolizumab, an immunotherapy drug, in people with advanced solid tumors who had already tried standard treatments that stopped working. Researchers enrolled 1,609 participants with various cancers including anal, cervical, lung, and thyroid cancers to see how…

This is an early-stage study to find a safe dose of a new immunotherapy drug called HFB200301. It is being tested alone and in combination with an existing drug (tislelizumab) in adults with advanced solid tumors who have already tried other treatments. The main goal is to see ho…

This is an early-stage study to test the safety and find the right dose of a new drug called PF-08046049/SGN-BB228. It is for adults with advanced solid tumors, including melanoma, lung, colorectal, pancreatic cancer, or mesothelioma, that have stopped responding to standard trea…

This early-stage trial is testing the safety and finding the right dose of a two-drug combination (naptumomab estafenatox and durvalumab) for people with advanced or metastatic solid tumors. It will enroll about 120 adults with one of many eligible cancer types, including breast,…

This study aimed to test if an oral drug called APG-115 could stop or slow the growth of early-stage mesothelioma in people with a specific inherited gene mutation (BAP1). Participants would have taken the drug at home in repeating cycles while undergoing regular scans and biopsi…

This study is testing whether an oral drug called INQOVI can stop or improve very early-stage mesothelioma in people born with a specific gene mutation (BAP1) that makes them highly likely to develop this cancer. Participants take the pill for six months while doctors closely mon…

This early-stage study is testing a new oral medication called IAG933 in adults with advanced cancers, including mesothelioma, that have specific genetic changes. The main goals are to find a safe dose and see how well the body handles the drug. Researchers will also look for ear…

This research study aims to learn about the biological features of how chest cancers like lung cancer, thymus tumors, and mesothelioma develop and spread. Researchers will analyze blood, tumor tissue, and other fluids from about 1000 patients to look for genetic markers. The goal…